aim
antivir
efficaci
oral
antimicrobi
rins
adequ
studi
term
potenti
clinic
signific
followup
vitro
studi
effect
oral
antisept
herp
simplex
viru
type
studi
undertaken
evalu
vivo
effect
essenti
oil
contain
oral
antisept
reduct
viral
titer
saliva
activ
viral
infect
method
patient
recruit
evalu
singl
visit
protocol
onset
perior
outbreak
consist
histor
clinic
recurr
herp
labiali
direct
immunofluoresc
cytolog
smear
lesionsor
fluid
use
confirm
herp
simplex
viru
type
ii
patient
randomli
assign
one
two
treatment
group
activ
ingredi
steril
water
control
viral
lesion
evalu
clinic
stage
accord
standard
protocol
salivari
fluid
sampl
taken
baselin
immedi
follow
rins
min
rins
repeat
trial
also
min
rins
sampl
evalu
viral
titer
result
compar
numer
sourc
microbi
contamin
dental
operatori
dental
unit
water
dispers
threeway
syring
water
coolant
ultrason
instrument
aerosol
patient
oral
fluid
produc
highspe
handpiec
repres
initi
sourc
potenti
infecti
agent
operatori
variou
method
current
develop
place
reduct
sourc
microbi
contamin
standard
autoclav
procedur
standard
precaut
preclud
transmiss
potenti
infecti
microbi
agent
sourc
patient
individu
within
dental
operatori
concern
patient
oral
microorgan
includ
numer
viral
bacteri
pathogen
potenti
mobil
bioaeros
way
highspe
manipul
air
water
handpiec
activ
sourc
cross
contamin
adequ
studi
date
antimicrobi
efficaci
oral
rins
although
assum
mani
instanc
also
adequ
studi
term
potenti
clinic
signific
reduc
elimin
risk
cross
contamin
studi
complet
bacteri
pathogen
leav
vivo
antivir
effect
commerci
mouthrins
less
well
document
project
undertaken
evalu
efficaci
listerin
antisept
la
morri
plain
nj
usa
mouthrins
versu
steril
water
control
reduct
infecti
viral
level
saliva
activ
viral
infect
human
herp
simplex
viru
select
test
viru
order
establish
model
show
reduct
infecti
virion
saliva
follow
rins
recommend
manufactur
antisept
mouthrins
contain
essenti
oil
well
establish
viral
shed
henc
recoveri
occur
variabl
level
human
saliva
prodrom
period
least
full
vesicular
stage
recurr
herpet
outbreak
arvin
prober
primarili
variat
clinic
protocol
determin
stage
lesion
recoveri
techniqu
standard
everi
studi
previou
work
laboratori
five
stage
clinic
variat
defin
see
tabl
research
determin
earli
recurr
herp
labiali
lesion
stage
clinic
evalu
repres
time
greatest
viral
shed
like
occur
arvin
prober
sinc
stage
variabl
period
new
vesicl
format
potenti
still
occur
degre
infecti
virion
recov
saliva
lesion
also
variabl
studi
undertaken
determin
patient
known
suffer
herp
reduct
salivari
viral
titer
might
accomplish
oral
rins
clinic
stage
two
complimentari
trial
test
efficaci
la
complet
trial
adult
patient
age
year
known
histori
suffer
viral
recurr
recruit
advis
report
clinic
facil
first
sign
prodrom
perior
viral
lesion
occur
advertis
state
patient
establish
histori
viral
recurr
consist
herp
clinician
examin
patient
refer
clinic
site
util
standard
criteria
determin
likelihood
herpet
infect
sinc
studi
design
onevisit
protocol
test
viru
determin
consist
direct
immunofluoresc
dif
microscopi
perform
first
outbreak
use
determin
analysi
sampl
warrant
two
trial
follow
inform
consent
patient
examin
medic
histori
obtain
softtissu
examin
perform
patient
randomli
assign
either
experiment
control
group
patient
sampl
group
met
viral
lesion
usual
patient
perior
tissu
stage
accord
standard
procedur
see
tabl
follow
examin
determin
patient
histori
correspond
clear
evid
like
recurr
herp
labiali
steril
swab
roll
labial
tissu
adjac
area
lesion
instanc
lesion
stage
evid
vesicular
ruptur
swab
touch
area
well
swab
immedi
roll
onto
slide
transport
laboratori
dif
viral
identif
addit
second
sampl
obtain
patient
consist
ml
pool
saliva
sampl
collect
steril
ml
centrifug
tube
sampl
immedi
transport
laboratori
volum
determin
sampl
aliquot
later
test
gener
procedur
includ
sampl
viral
identif
baselin
follow
patient
instruct
rins
either
cm
experiment
mouthrins
cool
mint
la
case
control
patient
cm
steril
distil
water
follow
rins
patient
expector
second
sampl
saliva
collect
post
rins
patient
instruct
wait
min
third
sampl
pool
saliva
collect
second
trial
carri
addit
patient
ident
first
trial
except
fourth
oral
sampl
taken
min
post
rins
sampl
transport
laboratori
test
complement
fixat
haemagglutin
immunolog
test
develop
assist
diagnosi
activ
herpet
infect
fluoresc
antibodi
test
also
call
dif
antibodi
test
hsv
gener
consid
extrem
reliabl
assay
avail
detect
viral
antigen
patient
sampl
arvin
prober
approach
sensit
specif
visual
tzanck
cell
specif
diagnosi
made
earlier
infect
arvin
prober
test
smear
taken
appli
clinic
laboratori
slide
fixat
ethanol
stain
dilut
phosphat
buffer
salin
pb
monoclon
antibodi
dako
corp
carpinteria
ca
usa
increas
edema
red
gener
present
site
patient
suffer
normal
recurr
vesicl
format
vesicl
gener
continu
form
variabl
period
time
usual
day
vesicl
continu
develop
older
area
begin
burst
combin
vesicl
crust
area
exud
usual
resembl
serum
present
new
vesicl
appear
howev
lesion
crust
often
coalesc
larger
scab
area
last
scab
area
slough
tissu
begin
return
normal
minor
erythema
left
conjug
fluorescein
stain
min
moist
chamber
room
temperatur
viral
antigen
evalu
evid
antigen
follow
sever
wash
pb
use
fluoresc
microscopi
primari
african
monkey
kidney
cell
cultur
vero
excel
indic
cell
evalu
cytopath
effect
cpe
hsv
crane
et
al
vero
cell
american
type
cultur
collect
atcc
grown
monolay
cm
plastic
tissu
cultur
flask
corn
ny
complet
medium
cm
addit
antibiot
penicillin
g
sodium
uml
streptomycin
sulfat
mgml
supplement
heatinactiv
fetal
bovin
serum
lglutamin
mm
hepe
buffer
mm
mem
sodium
pyruv
mm
cell
incub
humidifi
atmospher
consist
co
posit
control
test
system
vero
cell
inocul
ml
mcintyr
strain
atcc
titer
previous
determin
standard
method
case
experiment
patient
sampl
vero
cell
allow
adsorb
ml
serial
dilut
sampl
h
gentl
rock
supernat
fluid
discard
estim
concentr
use
plaqu
assay
standard
procedur
use
plaqu
assay
use
vero
cell
threeday
grown
monolay
vero
cell
triplic
falcon
petri
dish
mm
overlay
either
ml
dilut
mcintyr
strain
aliquot
titrat
dilut
salivari
sampl
patient
petri
dish
monolay
uninfect
vero
cell
includ
neg
control
follow
adsorpt
aspir
supernat
fluid
plate
overlay
cm
concentr
methyl
cellulos
vv
solut
plate
incub
undisturb
co
examin
daili
day
supernat
fluid
aspir
plate
end
day
plaqu
count
clear
zone
within
monolay
cell
express
plaqu
form
unit
per
ml
pfuml
statist
analys
perform
data
use
pair
student
test
compar
differ
control
experiment
group
pretreat
post
treatment
min
post
treatment
case
trial
min
post
treatment
time
period
pvalu
less
consid
signific
ninetytwo
patient
demonstr
clinic
evid
recurr
herp
labiali
andor
report
histori
consist
recurr
herpet
perior
lesion
evalu
trial
four
patient
trial
eight
patient
nonreact
dif
therefor
evalu
sampl
perform
trial
sampl
popul
consist
male
femal
averag
age
year
lesion
clinic
evalu
accord
stage
scale
describ
tabl
twentyf
patient
demonstr
lesion
consist
stage
seven
patient
stage
earli
ruptur
vesicl
eight
patient
demonstr
mild
erythema
evid
prodrom
stage
patient
randomli
assign
either
control
experiment
group
sampl
taken
result
trial
experiment
illustr
tabl
fig
thirtyeight
patient
dif
react
monoclon
antibodi
two
patient
react
male
femal
patient
clinic
photograph
typic
stage
lesion
shown
fig
although
patient
accru
randomli
tabl
present
patient
receiv
experiment
rins
list
number
control
data
indic
experiment
patient
demonstr
zero
recover
virion
follow
rins
nine
patient
remain
zero
follow
min
delay
patient
return
log
recover
sampl
preevalu
recover
virion
consist
literatur
arvin
prober
util
viral
shed
saliva
trial
averag
age
year
femal
male
twentynin
stage
three
stage
eight
stage
lesion
evalu
two
reaction
note
dif
eighteen
patient
zero
recover
virion
post
rins
remain
zero
min
log
reduct
compar
trial
min
post
rins
patient
shed
log
lower
prerins
level
trial
control
patient
data
compar
trial
fig
tabl
recoveri
rate
consist
control
sampl
experiment
sampl
control
patient
well
distribut
gender
age
distribut
experiment
patient
rins
steril
distil
water
result
log
reduct
recover
virion
sampl
howev
return
number
compar
prerins
state
found
min
data
indic
direct
effect
la
viral
kill
residu
effect
min
gener
log
level
reduct
follow
statist
analysi
signific
differ
found
control
experiment
group
baselin
signific
differ
found
control
group
experiment
group
follow
rins
signific
differ
found
control
group
experiment
group
min
post
rins
control
compar
cours
trial
experi
signific
chang
note
post
rins
time
period
time
period
compar
baselin
howev
trend
log
reduct
use
steril
distil
water
rins
experiment
subject
compar
cours
experi
signific
reduct
found
baselin
post
rins
baselin
post
min
rins
studi
investig
antimicrobi
efficaci
mouthrins
la
found
complet
kill
microorgan
includ
methicillinresist
staphylococcu
aureu
streptococcu
pyogen
helicobact
pylori
candida
albican
streptococcu
mutan
actinomyc
viscosu
porphyromona
gingivali
prevotella
intermedia
actinobacillu
actinomycetemcomitan
within
expos
la
okuda
et
al
studi
la
also
report
weakli
inactiv
virus
okuda
et
al
dennison
et
al
found
chlorhexidin
complet
inhibit
hsv
influenza
viru
exposur
time
wherea
rotaviru
nonenvelop
viru
minim
inhibit
dennison
et
al
sever
investig
also
report
antihsv
effect
la
also
found
compar
ineffect
la
chlorhexidin
nonenvelop
virus
bernstein
et
al
croughan
behbehani
park
park
vitro
studi
baqui
et
al
la
found
possess
slightli
better
antihsv
effect
chlorhexidin
work
also
confirm
antivir
effect
la
mcintyr
strain
extend
effect
anoth
envelop
viru
vitro
studi
develop
semiquantit
tissu
cultur
assay
measur
inactiv
presenc
differ
dilut
reagent
use
util
sensit
cpe
rel
rapid
inexpens
simpl
method
determin
infect
vitro
vivo
estim
effect
util
standard
plaqu
format
assay
monolay
vero
cell
current
vivo
studi
effect
rins
essenti
oil
contain
mouthrins
cool
mint
la
result
effect
zero
recover
virion
post
rins
reduct
viral
presenc
saliva
remain
signific
reduct
approxim
min
experiment
patient
continu
reduct
min
post
rins
trial
rins
control
steril
distil
water
result
statist
nonsignific
reduct
viral
presenc
saliva
chang
baselin
min
result
consist
previou
find
effect
la
envelop
virus
report
dennison
et
al
investig
wood
payn
implic
studi
coupl
vitro
studi
previous
publish
baqui
et
al
clinic
efficaci
util
oral
rins
antimicrobi
agent
la
reduc
viral
contamin
saliva
clinic
signific
may
reduct
infecti
viru
level
level
demonstr
experi
significantli
reduc
may
elimin
risk
cross
contamin
necessari
level
infect
saliva
determin
may
subject
futur
studi
addit
clinic
implic
effect
antimicrobi
rins
envelop
virus
consist
literatur
virus
coronaviru
recent
identifi
sar
mcintosh
mufson
may
also
affect
rins
antimicrobi
agent
la
societ
valu
rins
accur
assess
howev
reduct
infecti
viru
level
least
theoret
reduc
risk
transmiss
uninfect
individu
f
f
f
f
f
f
f
f
f
f
f
f
f
f
dif
direct
immunofluoresc
assay
la
listerin
antisept
hsv
herp
simplex
viru
male
f
femal
pfu
plaqu
form
unit
